ArticleJACC. Asia2026
Prognostic Impact of Supranormal LVEF Following Mitral Valve TEER in Patients With Secondary Atrial MR.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management Implications of Atrial FMR and Advanced HFpEF: Lessons From Supra-normal LVEF.JACC. Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe concept of supranormal left ventricular ejection fraction (snLVEF) has recently gained prominence. Among patients with heart failure and preserved ejection fraction, those exhibiting snLVEF have demonstrated worse clinical outcomes compared to individuals with normal left ventricular ejection fraction (LVEF). However, the prognostic implications of snLVEF in the context of transcatheter edge-to-edge repair (TEER) for secondary atrial mitral regurgitation remain insufficiently elucidated.
objectivesThe purpose of this study was to investigate the prognostic impact of snLVEF in patients receiving TEER for secondary atrial mitral regurgitation.
methodsThis study evaluated patients with an LVEF ≥50% who underwent TEER using the MitraClip system for secondary atrial mitral regurgitation, as documented in the multicenter, investigator-initiated OCEAN-Mitral registry. snLVEF was defined as an LVEF ≥65%. The association between baseline snLVEF and 2-year mortality following TEER was analyzed.
resultsThe study included 529 patients (median age 83 years, 213 men). Of these, 137 patients were identified with snLVEF, while the remainder exhibited normal LVEF. Patients with snLVEF were characterized by smaller left ventricular dimensions and more severe tricuspid regurgitation relative to those with normal LVEF. The presence of snLVEF was independently associated with a significantly elevated risk of 2-year mortality following TEER, with an adjusted HR of 1.86 (95% CI: 1.21-2.86; P = 0.005).
conclusionssnLVEF emerged as an independent predictor of increased mortality following TEER for secondary atrial mitral regurgitation vs normal LVEF. (OCEAN-Mitral registry; UMIN000023653).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.